Table 2.
Monthly migraine days, Migraine-Specific Quality of Life Questionnaire v2, and EuroQol five-dimension three-level utility at baseline and change from baseline (52 weeks for the PRN groups and 12 weeks for the QOD + PRN group)
| 2–8 MMD PRN (n = 1033) | 9–14 MMD PRN (n = 286) | 4–14 MMD QOD + PRN (n = 481) | |
|---|---|---|---|
| MMD at baseline | 7.02 (3.74) | 12.23 (4.64) | 9.03 (3.90) |
| MMD change from baseline | − 0.47 (− 0.84, − 0.11) | − 2.94 (− 3.65, − 2.24) | − 3.31 (− 3.75, − 2.87) |
| MSQv2- RP at baseline | 69.28 (20.45) | 64.47 (20.75) | 68.06 (19.73) |
| MSQv2—RP change from baseline | 13.78 (12.30, 15.26) | 15.60 (13.17, 18.04) | 18.98 (16.44, 21.51) |
| MSQv2—RR at baseline | 54.56 (18.25) | 48.70 (18.44) | 52.26 (17.38) |
| MSQv2—RR change from baseline | 16.82 (15.31, 18.33) | 19.86 (17.49, 22.23) | 24.27 (21.94, 26.61) |
| MSQv2—EF at baseline | 63.70 (25.62) | 54.87 (26.23) | 60.84 (25.47) |
| MSQv2—EF change from baseline | 16.72 (14.83, 18.60) | 19.49 (16.21, 22.77) | 24.02 (20.95, 27.08) |
| Mapped EQ-5D-3L utility at baseline | 0.66 (0.12) | 0.63 (0.12) | 0.65 (0.11) |
| Mapped EQ-5D-3L utility change from baseline | 0.09 (0.08, 0.10) | 0.10 (0.09, 0.11) | 0.12 (0.11, 0.14) |
Baseline values are mean (SD), CFB values are mean (95% CI)
EF emotional function; MMD monthly migraine days; MSQv2 migraine-specific quality of life; n number of participants in each group; RP role preventive; RR role restrictive; SD standard deviation